Search: onr:"swepub:oai:DiVA.org:umu-46692" >
Correlation between...
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
-
- Herzog, Thomas J. (author)
- Columbia University College of Physicians and Surgeons, New York, NY, USA
-
- Vermorken, Jan B. (author)
- Antwerp University Hospital, Edegem, Belgium
-
- Pujade-Lauraine, Eric (author)
- Hôspital Hotel-Dieu, Paris, France
-
show more...
-
- Provencher, Diane M. (author)
- Hôpital Notre-Dame, Montréal (Qc) H2L 4M1, Canada
-
- Jagiello-Gruszfeld, Agnieszka (author)
- Memorial Cancer Center, Warszawa, Poland
-
- Kong, Beihua (author)
- Qilu Hospital, Shandong University, Shandong, China
-
- Boman, Karin (author)
- Umeå universitet,Onkologi
-
- Park, Youn Choi (author)
- Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA
-
- Parekh, Trilok (author)
- Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA
-
- Lebedinsky, Claudia (author)
- PharmaMar, Colmenar Viejo, Madrid, Spain
-
- Gomez, Javier (author)
- PharmaMar, Colmenar Viejo, Madrid, Spain
-
- Monk, Bradley J. (author)
- Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a member of Catholic Healthcare West, Phoenix, AZ, USA
-
show less...
-
(creator_code:org_t)
- New York : Elsevier BV, 2011
- 2011
- English.
-
In: Gynecologic Oncology. - New York : Elsevier BV. - 0090-8258 .- 1095-6859. ; 122:2, s. 350-355
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Objectives: To evaluate in a large phase III recurrent ovarian cancer trial (OVA-301): 1) the concordance between CA-125 level vs. best overall response (OR) and progression-free survival (PFS) determined by radiological assessment 2) the impact of early CA-125 changes over the subsequent radiological response, and 3) the prognostic value of CA-125 response and CA-125 PFS to predict radiological response and PFS. Methods: Assessment of response in the entire randomized population was performed by the Response Evaluation Criteria in Solid Tumors 1.0 (RECIST) and modified Rustin criteria for CA-125 determination. Results: Most CA-125 decreases were observed in RECIST responders (82% of patients treated with the combination and 74% in the PLD alone). CA-125 progression preceded REC1ST progression in 35% of patients with a median lead time of 8.4 weeks. A high concordance rate between CA-125 PFS status at 4 months (PFS4) and CA-125 response as a predictor of PFS4 (87%) and radiological response (79%) was found in the combination, with high positive predictive value for radiological PFS4 (92%) and high negative predictive value for OR (90%). An early CA-125 decrease was predictive for the ultimate response since it was found in a high rate of RECIST responders. Conclusion: Radiological response was preceded by a favorable predictive CA-125 decrease in a high proportion of patients, suggesting that CA-125 evaluation may be an appropriate tool for tumor assessment in patients with ovarian cancer.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- CA-125
- Rustin criteria
- Platinum
- Relapsed ovarian cancer
- Trabectedin
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Herzog, Thomas J ...
-
Vermorken, Jan B ...
-
Pujade-Lauraine, ...
-
Provencher, Dian ...
-
Jagiello-Gruszfe ...
-
Kong, Beihua
-
show more...
-
Boman, Karin
-
Park, Youn Choi
-
Parekh, Trilok
-
Lebedinsky, Clau ...
-
Gomez, Javier
-
Monk, Bradley J.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Gynecologic Onco ...
- By the university
-
Umeå University